# US 2012/0251555 A1 · Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251555 A1
- Document ID: US20120251555A1
- Status: Published application
- Kind: A1
- Application number: 13/305,898
- Filed: 2011-11-29
- Published: 2012-10-04
- Earliest claimed: 2003-03-19
- Assignees: Celldex Therapeutics, Inc.; Amgen Fremont Inc.
- Inventors: Gregory M. Landes; Francine Chen; Binyam Bezabeh; Ian Foltz; Kam Fai Tse; Michael Jeffers; Mehdi Mesri; Gary Starling; Peter Mezes; Nikolia Khramtsov
- Web page: https://patentgrep.com/patent/US20120251555A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 51/1039: {against T-cell receptors}
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- G01N 33/575: for cancer
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/50: characterized by immunoglobulin fragments
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

## Claims

### Claim 1

An isolated human antibody, or binding fragment thereof, that specifically binds to T cell, immunoglobulin domain and mucin domain 1 (TIM-1).

### Claim 2 (depends on 1)

The antibody of claim 1, wherein said TIM-1 comprises the amino acid sequence shown in SEQ ID NO:54.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein said TIM-1 comprises the amino acid sequence of SEQ ID NO:87.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein said antibody is a monoclonal antibody.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein said binding fragment comprises a Fab, Fab′, F(ab′)2, or Fv fragment of said antibody.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein said antibody is a single chain antibody.

### Claim 7 (depends on 1)

The antibody, or binding fragment, of claim 1, wherein said antibody or binding fragment is associated with a pharmaceutically acceptable carrier or diluent.

### Claim 8 (depends on 1)

The antibody, or binding fragment of claim 1, wherein the antibody or binding fragment is conjugated to a therapeutic agent.

### Claim 9 (depends on 8)

The antibody, or binding fragment of claim 8, wherein the therapeutic agent is a toxin.

### Claim 10 (depends on 8)

The antibody or binding fragment of claim 8, wherein the therapeutic agent is a radioactive isotope.

### Claim 11 (depends on 8)

The antibody or binding fragment of claim 8, wherein the therapeutic agent is a chemotherapeutic agent.

### Claim 12 (depends on 1)

A hybridoma cell line producing the antibody, or binding fragment, of claim 1.

### Claim 13 (depends on 1)

A transformed cell comprising a gene encoding the antibody, or binding fragment, of claim 1.

### Claim 14 (depends on 13)

The transformed cell of claim 13, wherein the cell is a Chinese hamster ovary (CHO) cell.

### Claim 15 (depends on 1)

A method of inhibiting cell proliferation associated with the expression of TIM-1, comprising treating cells expressing TIM-1 with an effective amount of the antibody of claim 1.

### Claim 16 (depends on 1)

A method of effectively treating renal cancer comprising:
identifying an animal in need of treatment for renal cancer;
administering to said animal a therapeutically effective dose of the antibody of claim 1.

### Claim 17 (depends on 1)

A method of effectively treating ovarian cancer comprising:
identifying an animal in need of treatment for ovarian cancer;
administering to said animal a therapeutically effective dose of the antibody of claim 1.

### Claim 18 (depends on 1)

An article of manufacture comprising a container, a composition contained therein, and a package insert or label indicating that the composition can be used to treat cancer characterized by the overexpression of TIM-1, wherein the composition comprises the antibody, or binding fragment, of claim 1.

### Claim 19 (depends on 1)

An assay kit for the detection of TIM-1 in mammalian tissues or cells in order to screen for lung, colon, gastric, kidney, renal, prostate or ovarian carcinomas, the TIM-1 being an antigen expressed by lung, colon, gastric, kidney, renal, prostate or ovarian carcinomas, the kit comprising the antibody of claim 1 and means for indicating the reaction of the antibody with the antigen, if present.

### Claim 20 (depends on 19)

The assay kit of claim 19, wherein the antibody is labeled.

### Claim 21 (depends on 19)

The assay kit of claim 19, wherein the antibody is an unlabeled first antibody and the means for indicating the reaction comprises a labeled second antibody that is anti-immunoglobulin.

### Claim 22 (depends on 21)

The assay kit of claim 21, wherein the antibody that binds the antigen is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radiopaque material.

### Claim 23 (depends on 22)

The assay kit of claim 22, wherein the second antibody is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radiopaque material.
